Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article, we are going to take a ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...

TORONTO, March 13, 2025 /PRNewswire/ -- Public Sector Pension Investment Board (PSP Investments), one of Canada's largest pension investors, today announced that it has entered into agreements to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Gvoke comes in three forms for subcutaneous injection: HypoPen auto-injector prefilled syringe prefilled vial and syringe kit To find out what the cost of Gvoke will be for you, talk with your ...

Reproxalap, a first-in-class small-molecule modulator of reactive aldehyde species (RASP), is under review for the treatment of the signs and symptoms of dry eye disease. It works by covalently ...

I'm proud to report that we exceeded our full year guidance with total revenue of over $203 million, growing 24% versus last year led by strong demand for Recorlev and Gvoke and continuing ...